Pazopanib 200 Mg Eurolab 200 mg and 400 mg FC tablet
PDF Leaflet Revision Date: 15 July 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of advanced and/or metastatic renal cell carcinoma.
Dosage (summary)
800 mg orally once daily; adjust in 200 mg increments based on tolerability.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; breastfeeding not established as safe.
Key Drug Interactions
- Strong CYP3A4 inhibitors
- Grapefruit juice
Contraindications
- Hypersensitivity to pazopanib
Common side effects
- Fatigue
- Hypertension
- Diarrhea
- Nausea
- Hypothyroidism
Counselling Points
- Take without food
- Monitor blood pressure
- Avoid pregnancy
- Report liver function changes
Serious warnings
- Hepatic failure
- Hypertension
- Cardiac dysfunction
- PRES/RPLS
- GI perforations
Important Disclaimer
The Pazopanib 200 Mg Eurolab 200 mg and 400 mg FC tablet professional information leaflet below is the property of Eurolab and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
